Top five pharmaceutical companies expected to fare well in second quarter

Despite the brunt of government-imposed price cuts and the stepped-up competition, the so-called “big five” drug makers in Korea will see their revenues increase in the second quarter of this year, unlike the original expectation.

Korea’s largest Dong-A Pharmaceutical is projected to post 240.6 billion won in the second quarter, up 7.2 percent compared with the same period from a year earlie...